Psychiatric disorders after starting dolutegravir: Report of four cases

AIDS

Volumn 29, Issue 13, 2015, Pages 1723-1725

  Kheloufi, Farid ^a   Allemand, Julie ^b   Mokhtari, Saadia ^c   Default, Anne ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b Centre Hospitalier Edmond Garcin   (France)

^c HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DOLUTEGRAVIR; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; RITONAVIR; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS;

ABNORMAL SENSATION; ADULT; ANXIETY DISORDER; CASE REPORT; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC DISORDER; MIDDLE AGED; PERSONALITY DISORDER; PRIORITY JOURNAL; SUICIDAL IDEATION; ADVERSE EFFECTS; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED; PROCEDURES; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; VIRAL LOAD;

EID: 84942510636     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000789     Document Type: Letter

References (12)

1. Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One 2013; 8:e52562.
2. Van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim48week results from SPRING-1, adose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111-118.
3. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 2013; 381:735-743.
4. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807-1818.
5. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222-2231.
6. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 2013; 207: 740-748.
7. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R. Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210:354-362.
8. Merck Sharp & Dohme Ltd. Isentress. Summary of products Characteristics. Hertfordshire, UK: Merck Sharp & Dohme Ltd; 2014.
9. Gilead Sciences International Limited. Vitekta. Summary of Products Characteristics. Cambridge, UK: Gilead Sciences International Limited; 2014.
10. ViiV Healthcare UK Limited. Tivicay. Summary of Products Characteristics. Brentford, UK: ViiV Healthcare UK Limited; 2014.
11. Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008; 22:1890-1892.
12. Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis 2014; 59:1032-1037.